| 16.08 1.03 (6.84%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.78  |
1-year : | 21.93 |
| Resists | First : | 16.07 |
Second : | 18.78 |
| Pivot price | 13.8 |
|||
| Supports | First : | 12.89 |
Second : | 10.92 |
| MAs | MA(5) : | 14.92 |
MA(20) : | 13.22 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 92.8 |
D(3) : | 86 |
| RSI | RSI(14): 70.3 |
|||
| 52-week | High : | 16.36 | Low : | 10.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SI ] has closed below upper band by 15.9%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 16.08 - 16.14 | 16.14 - 16.19 |
| Low: | 14.78 - 14.85 | 14.85 - 14.91 |
| Close: | 15.96 - 16.07 | 16.07 - 16.16 |
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Tue, 18 Nov 2025
Shoulder Innovations (NYSE: SI) debuts InSet 70 humeral stem for shoulder arthroplasty - Stock Titan
Tue, 11 Nov 2025
Shoulder Innovations Reports Third Quarter 2025 Financial Results and Increases Full-Year Revenue Guidance - PR Newswire
Tue, 04 Nov 2025
Shoulder Innovations to Participate in the Jefferies Global Healthcare Conference - Sahm
Mon, 20 Oct 2025
Shoulder Innovations to Report Third Quarter 2025 Financial Results on November 11, 2025 - BioSpace
Mon, 20 Oct 2025
Shoulder Innovations (NYSE: SI) sets Nov. 11 earnings call for 4:30 p.m. ET - Stock Titan
Mon, 22 Sep 2025
Shoulder Innovations Announces Full Commercial Launch of the InSet™ 70 Humeral Stem - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|